• Allos Therapeutics Inc., of Westminster, Colo., initiated patient enrollment in a Phase I trial of its targeted chemotherapeutic agent RH1 in patients with advanced solid tumors or non-Hodgkin's lymphoma. In the dose-escalation study, up to 60 patients will receive a three-hour intravenous infusion of RH1 administered once every 21 days.

• Archemix Corp., of Cambridge, Mass., started a Phase IIa trial of ARC1779, which is designed to test the drug's safety and efficacy as an anti-thrombotic in patients with acute coronary syndrome undergoing emergency percutaneous coronary intervention. ARC1779 is an aptamer designed to bind to and inhibit the function of the von Willebrand Factor protein, which initiates and promotes platelet clot formation in the arterial circulation in ACS patients. The 300-patient trial, which will use ReoPro as a comparator, has co-primary endpoints defined as the degree of myocardial perfusion and the deficit of blood supply to the working heart muscle following PCI.

• Inspiration Biopharmaceuticals, of Laguna Niguel, Calif., filed an investigational new drug application to start clinical trials with IB1001, an intravenous recombinant Factor IX product for the on-demand and prophylactic treatment of the bleeding disorder associated with hemophilia B. Upon FDA clearance, Inspiration intends to initiate Phase I/II trials to test the drug against commercially available Factor IX products.

• Isis Pharmaceuticals Inc., of Carlsbad, Calif., said results from its Phase II study of mipomersen (ISIS 301012) in patients with routine high cholesterol showed that, in eight patients on stable doses of less than or equal to 40 mg/day of statins who were treated with 200 mg/week mipomersen for three months, a 42 percent reduction was seen in apoB, and a 48 percent reduction was seen in low-density lipoprotein cholesterol, beyond reductions achieved with statin therapy alone. Isis also reported results of an integrated safety analysis, demonstrating that mipomersen has been well tolerated and that treatment did not result in evidence of liver toxicity.

• Provectus Pharmaceuticals Inc., of Knoxville, Tenn., was cleared to begin Phase II testing of PH-10, a topical dermatology drug, in psoriasis. The study will enroll 25 patients with moderate to severe forms of the disease, who will apply PH-10 twice-weekly for up to 12 weeks to psoriatic plaque areas. Response will be observed throughout the treatment phase, and for one month after, and will be graded using the Psoriasis Severity Index and an investigator's clinical assessment of plaque response.